Jonathan Savitz1,2, Bart N Ford3, Rayus Kuplicki4, Sahib Khalsa4,5, T Kent Teague6,7,8, Martin P Paulus4,5. 1. Laureate Institute for Brain Research, Tulsa, OK, USA. jsavitz@laureateinstitute.org. 2. Oxley College of Health Sciences, The University of Tulsa, Tulsa, OK, USA. jsavitz@laureateinstitute.org. 3. Department of Pharmacology & Physiology, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA. 4. Laureate Institute for Brain Research, Tulsa, OK, USA. 5. Oxley College of Health Sciences, The University of Tulsa, Tulsa, OK, USA. 6. Department of Surgery, University of Oklahoma School of Community Medicine, Tulsa, OK, USA. 7. Department of Psychiatry, University of Oklahoma School of Community Medicine, Tulsa, OK, USA. 8. Department of Pharmaceutical Sciences, University of Oklahoma College of Pharmacy, Tulsa, OK, USA.
Abstract
RATIONALE: At least six different types of antidepressant treatments have been shown to either increase the neuroprotective kynurenine pathway (KP) metabolite, kynurenic acid (KynA), or decrease the neurotoxic KP metabolite, quinolinic acid (QA). Nonsteroidal anti-inflammatory drugs (NSAIDs) including ibuprofen have shown some efficacy in the treatment of depression but their effects on the KP have not been studied in humans. OBJECTIVES: To evaluate the effect of ibuprofen on circulating KP metabolites. METHODS: In a randomized, placebo-controlled, crossover study, 20 healthy adults (10 women) received a single oral dose of 200-mg ibuprofen, 600-mg ibuprofen, or placebo in a counterbalanced order (NCT02507219). Serum samples were drawn in the mid-afternoon, 5 h after ibuprofen/placebo administration. KP metabolites were measured blind to visit by tandem mass spectrometry. Data were analyzed with linear mixed effect models. The primary outcome was KynA/QA and the secondary outcome was KynA. RESULTS: After Bonferroni correction, there was a significant effect of treatment on KynA/QA. The effect was driven by an increase in KynA concentration after the 600-mg dose but not the 200-mg dose relative to placebo (Cohen's d = 1.71). In contrast, both the 200-mg (d = 1.03) and 600-mg (d = 2.05) doses of ibuprofen decreased tryptophan concentrations relative to placebo. CONCLUSIONS: Given its KynA-elevating effects, ibuprofen could have neuroprotective effects in the context of depression as well as other neuroinflammatory disorders that are characterized by a reduction in KynA.
RATIONALE: At least six different types of antidepressant treatments have been shown to either increase the neuroprotective kynurenine pathway (KP) metabolite, kynurenic acid (KynA), or decrease the neurotoxic KP metabolite, quinolinic acid (QA). Nonsteroidal anti-inflammatory drugs (NSAIDs) including ibuprofen have shown some efficacy in the treatment of depression but their effects on the KP have not been studied in humans. OBJECTIVES: To evaluate the effect of ibuprofen on circulating KP metabolites. METHODS: In a randomized, placebo-controlled, crossover study, 20 healthy adults (10 women) received a single oral dose of 200-mg ibuprofen, 600-mg ibuprofen, or placebo in a counterbalanced order (NCT02507219). Serum samples were drawn in the mid-afternoon, 5 h after ibuprofen/placebo administration. KP metabolites were measured blind to visit by tandem mass spectrometry. Data were analyzed with linear mixed effect models. The primary outcome was KynA/QA and the secondary outcome was KynA. RESULTS: After Bonferroni correction, there was a significant effect of treatment on KynA/QA. The effect was driven by an increase in KynA concentration after the 600-mg dose but not the 200-mg dose relative to placebo (Cohen's d = 1.71). In contrast, both the 200-mg (d = 1.03) and 600-mg (d = 2.05) doses of ibuprofen decreased tryptophan concentrations relative to placebo. CONCLUSIONS: Given its KynA-elevating effects, ibuprofen could have neuroprotective effects in the context of depression as well as other neuroinflammatory disorders that are characterized by a reduction in KynA.
Authors: Leandro Z Agudelo; Teresa Femenía; Funda Orhan; Margareta Porsmyr-Palmertz; Michel Goiny; Vicente Martinez-Redondo; Jorge C Correia; Manizheh Izadi; Maria Bhat; Ina Schuppe-Koistinen; Amanda T Pettersson; Duarte M S Ferreira; Anna Krook; Romain Barres; Juleen R Zierath; Sophie Erhardt; Maria Lindskog; Jorge L Ruas Journal: Cell Date: 2014-09-25 Impact factor: 41.582
Authors: Cecilie Bay-Richter; Klas R Linderholm; Chai K Lim; Martin Samuelsson; Lil Träskman-Bendz; Gilles J Guillemin; Sophie Erhardt; Lena Brundin Journal: Brain Behav Immun Date: 2014-08-12 Impact factor: 7.217
Authors: Kelly T Cosgrove; Rayus Kuplicki; Jonathan Savitz; Kaiping Burrows; W Kyle Simmons; Sahib S Khalsa; T Kent Teague; Robin L Aupperle; Martin P Paulus Journal: Brain Behav Immun Date: 2021-05-27 Impact factor: 19.227
Authors: Kaiping Burrows; Leandra K Figueroa-Hall; Rayus Kuplicki; Jennifer L Stewart; Ahlam M Alarbi; Rajagopal Ramesh; Jonathan B Savitz; T Kent Teague; Victoria B Risbrough; Martin P Paulus Journal: Sci Rep Date: 2022-01-17 Impact factor: 4.379
Authors: Michael Berk; Mohammadreza Mohebbi; Olivia M Dean; Sue M Cotton; Andrew M Chanen; Seetal Dodd; Aswin Ratheesh; G Paul Amminger; Mark Phelan; Amber Weller; Andrew Mackinnon; Francesco Giorlando; Shelley Baird; Lisa Incerti; Rachel E Brodie; Natalie O Ferguson; Simon Rice; Miriam R Schäfer; Edward Mullen; Sarah Hetrick; Melissa Kerr; Susy M Harrigan; Amelia L Quinn; Catherine Mazza; Patrick McGorry; Christopher G Davey Journal: BMC Med Date: 2020-01-17 Impact factor: 8.775